Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 408

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 408
---
 This discussion and analysis should be read together with the section of this proxy statement / prospectus entitled “Selected Historical Financial Information of OmnigenicsAI”, the audited combined financial statements, and related notes of OmnigenicsAI that are included elsewhere in this proxy statement / prospectus, which include financial data for the year ended June 30, 2024 and as of June 30, 2024 . This discussion and analysis should also be read together with the unaudited interim condensed combined financial statements for the six -month period ended December 31, 2024, the section of this proxy statement / prospectus entitled “Business of the Company and Information About the Company” and the unaudited pro forma combined consolidated financial information for the year ended June 30, 2024, and as of and for the six -month period ended December 31, 2024 in the section of this proxy statement / prospectus entitled “Unaudited Pro Forma Combined Financial Information.” In addition to historical financial information, this discussion and analysis contains forward -looking statements based upon current expectations that involve risks, uncertainties and assumptions. See the section entitled “Cautionary Note Regarding Forward -Looking Statements.” Actual results and timing of selected events may differ materially from those anticipated in these forward -looking statements as a result of various factors, including those set forth under “Risk Factors” or elsewhere in this proxy statement / prospectus. Overview Prior to the Heritas Contribution (as defined below), we have substantially conducted our business operations through Heritas Argentina. Heritas Argentina was incorporated on July 10, 2015 and is registered with the public registry of Rosario, circunscripciónN°1, Santa Fe, Argentina, under the number T98 F252 N12. It initially focused on developing proprietary clinical tests in genomics and reproductive health. Leveraging Bioceres’ scientific team and CIBIC’s extensive experience in clinical diagnostics, Heritas Argentina successfully launched precision medicine products and services, and it specializes in clinical genetic services, offering tests that cater to diverse medical fields such as oncology, prenatal care, and rare diseases. In response to changing consumer habits which resulted from the COVID -19pandemic, Heritas Argentina expanded its offerings by launching Rewell, a direct -to -consumerbrand focused on at -homeDNA and microbiome testing. Rewell aims to empower consumers through personalized health data to enhance their long -termwell -beingthrough optimal lifestyle choices. In addition, Rewell’s services include a